Critical Outcome Technologies (OTCMKTS:COTQF – Get Free Report) and Lipocine (NASDAQ:LPCN – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.
Analyst Recommendations
This is a breakdown of current recommendations for Critical Outcome Technologies and Lipocine, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Critical Outcome Technologies | 0 | 0 | 0 | 0 | 0.00 |
| Lipocine | 1 | 1 | 0 | 1 | 2.33 |
Lipocine has a consensus price target of $15.00, suggesting a potential upside of 543.78%. Given Lipocine’s stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Critical Outcome Technologies.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Critical Outcome Technologies | N/A | N/A | N/A | N/A | N/A |
| Lipocine | $1.98 million | 9.70 | -$9.63 million | ($1.88) | -1.24 |
Critical Outcome Technologies has higher earnings, but lower revenue than Lipocine.
Institutional & Insider Ownership
9.1% of Lipocine shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Critical Outcome Technologies and Lipocine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Critical Outcome Technologies | N/A | N/A | N/A |
| Lipocine | -571.18% | -66.70% | -59.39% |
Summary
Lipocine beats Critical Outcome Technologies on 6 of the 9 factors compared between the two stocks.
About Critical Outcome Technologies
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
About Lipocine
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Critical Outcome Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
